Rh Incompatibility in Pregnancy: Causes, Diagnosis, and Management

Rh Incompatibility in Pregnancy: Causes, Diagnosis, and Management 

Introduction

Rh incompatibility is a significant immuno-hematological condition that can affect pregnancy outcomes. It arises when a pregnant woman with Rh-negative blood carries a fetus with Rh-positive blood. Without proper management, this condition can lead to serious fetal and neonatal complications, including hemolytic disease of the fetus and newborn (HDFN). Advances in prenatal care, especially the use of anti-D immunoglobulin, have dramatically reduced its incidence and severity.

What is Rh Factor?

The Rh factor is a protein found on the surface of red blood cells. Individuals are classified as:

• Rh-positive: Presence of Rh antigen (D antigen)
• Rh-negative: Absence of Rh antigen

Rh incompatibility occurs when an Rh-negative mother is exposed to Rh-positive fetal red blood cells, leading to an immune response.

Pathophysiology of Rh Incompatibility

The condition is based on maternal alloimmunization:

1. Fetal Rh-positive red blood cells enter maternal circulation (feto-maternal hemorrhage).
2. The maternal immune system recognizes these cells as foreign.
3. Maternal IgG antibodies against Rh antigen are produced.
4. In subsequent pregnancies, these antibodies cross the placenta.
5. Antibodies destroy fetal red blood cells, causing hemolysis.

This immune-mediated destruction can result in:

• Fetal anemia
• Hyperbilirubinemia
• Hydrops fetalis
• Intrauterine fetal demise (severe cases)

Risk Factors

Several factors increase the risk of Rh incompatibility:

• Previous Rh-positive pregnancy
• Miscarriage or abortion
• Ectopic pregnancy
• Invasive procedures (e.g., amniocentesis)
• Placental abruption or trauma
• Blood transfusion with Rh-positive blood

Clinical Manifestations

In the Fetus

• Anemia
• Hydrops fetalis (generalized edema)
• Hepatosplenomegaly
• Heart failure (in severe anemia)

In the Newborn

• Jaundice within 24 hours
• Kernicterus (bilirubin-induced brain damage)
• Pallor and anemia

Diagnosis

Maternal Testing

• Blood group and Rh typing
• Indirect Coombs test (detects maternal antibodies)

Fetal Assessment

• Middle cerebral artery Doppler (to assess fetal anemia)
• Ultrasound (hydrops fetalis detection)
• Amniocentesis (bilirubin levels in amniotic fluid)

Neonatal Testing

• Direct Coombs test
• Hemoglobin and bilirubin levels

Prevention

The cornerstone of prevention is anti-D immunoglobulin (Rho(D) immune globulin):

When is it given?

• At 28 weeks of gestation
• Within 72 hours after delivery (if baby is Rh-positive)
• After miscarriage, abortion, or invasive procedures

Mechanism of Action

Anti-D immunoglobulin prevents maternal sensitization by destroying fetal Rh-positive cells before the maternal immune system reacts.

Complications

If untreated, Rh incompatibility can lead to:

• Severe fetal anemia
• Hydrops fetalis
• Stillbirth
• Neonatal kernicterus
• Long-term neurological damage 

Prognosis

With early detection and proper prophylaxis, the prognosis is excellent. The introduction of anti-D immunoglobulin has reduced the incidence of Rh sensitization to less than 1% in developed healthcare systems.

SEO Keywords

Rh incompatibility in pregnancy, Rh negative mother, Rh positive fetus, hemolytic disease of the newborn, anti-D immunoglobulin, Rh isoimmunization, pregnancy complications, fetal anemia, hydrops fetalis.

Conclusion

Rh incompatibility remains a preventable yet potentially serious condition in obstetrics. Early screening, appropriate prophylaxis, and timely intervention are essential in ensuring favorable maternal and fetal outcomes. Education and adherence to antenatal care protocols play a crucial role in eliminating complications associated with this condition.

References

1. Cunningham, F. G., et al. (2022). Williams Obstetrics (26th ed.). McGraw-Hill.
2. Royal College of Obstetricians and Gynaecologists (RCOG). (2014). The Management of Women with Red Cell Antibodies during Pregnancy.
3. American College of Obstetricians and Gynecologists (ACOG). (2018). Prevention of Rh D Alloimmunization. Practice Bulletin No. 181.
4. Moise, K. J. (2008). Management of rhesus alloimmunization in pregnancy. Obstetrics & Gynecology, 112(1), 164–176.
5. World Health Organization (WHO). (2016). Guidelines for the prevention and treatment of Rh disease.
6. Bowman, J. M. (2006). RhD hemolytic disease of the newborn. New England Journal of Medicine, 339, 1775–1777.

Medical Disclaimer

The information provided on this website is for educational and informational purposes only.

Although the content is related to medical topics such as pregnancy and women’s health, it should not be considered professional medical advice, diagnosis, or treatment.

Always seek the advice of a qualified healthcare professional regarding any medical condition or health concern.

The author and website are not responsible for any actions taken based on the information provided on this site.

 Dr.Ifrah Hassan Hilaac.

https://www.drifrahhassanhilac.com/2026/03/preeclampsia.html